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Abstract 
 
Cervical cancer is one of the major women health problems, which is considered to be 
responsible for significant percentage of cancer related deaths in low and middle 
income countries. While Human Papilloma virus (HPV) DNA testing has an established 
role in cervical cancer prevention, there is a need to use other biomarkers with higher 
specificity and prognostic value to recognize patients at risk of progressive illness. There 
are evidences suggest that, direct detection of HPV messenger RNA transcripts may 
establish a more specific method for defining clinically important infection than viral 
DNA detection. Our objective was to provide an overview of the literature on specificity 
of HPV mRNA testing compared to DNA testing for detecting the risk evaluation of 
cervical intraepithelial neoplasia and invasive cervical cancer. We focused on recent 
clinical studies that support the application of HPV E6/E7 mRNA as a marker in 
advanced cervical cancer screening program. We provide overview of sample size, 
recruitment setting, age, HPV mRNA and HPV DNA assays for researches included in our 
review. The pooled review of clinical studies provided evidence that HPV mRNA might 
be a relevant diagnostic biomarker but additional studies need to be developed in 
order to make strong conclusion. 
 
Keywords: Cervical cancer detection, HPV mRNA, biomarker  
 
Abstrak 
 
Kanser serviks merupakan salah satu masalah utama kesihatan wanita yang 
bertanggungjawab dalam peratusan kematian disebabkan kanser yang signifikan di 
negara-negara berpendapatan rendah dan sederhana. Walaupun ujian DNA virus 
papiloma manusia (HPV) terbukti berperanan dalam pencegahan kanser serviks, 
terdapat keperluan untuk menggunakan penanda bio lain dengan kespesifikan dan 
nilai prognostik yang lebih tinggi untuk mengesan pesakit-pesakit berisiko penyakit 
progresif. Terdapat bukti yang mencadangkan bahawa pengesanan secara langsung 
transkrip RNA pengutus (mRNA) HPV memungkinkan pewujudan kaedah yang lebih 
spesifik untuk pentakrifan infeksi klinikal yang penting berbanding dengan pengesanan 
DNA virus. Objektif kami adalah untuk memberikan gambaran keseluruhan literatur 
berkaitan dengan kespesifikan pengujian mRNA HPV berbanding dengan pengujian 
DNA untuk mengesan risiko neoplasia intraepitelium serviks dan kanser serviks invasif. 
Kami fokus pada kajian klinikal terkini yang menyokong aplikasi mRNA HPV E6/E7 
sebagai penanda dalam program penyaringan kanser serviks lanjutan. Kami 
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memberikan di sini suatu gambaran keseluruhan saiz sampel, penetapan perekrutan, 
umur, asai-asai mRNA HPV dan DNA HPV untuk penyelidikan-penyelidikan yang 
termasuk dalam ulasan kami. Ulasan kajian-kajian klinikal yang terkumpul membuktikan 
bahawa mRNA HPV berkemungkinan menjadi penanda bio diagnostik yang relevan 
tetapi kajian tambahan perlu dihasilkan untuk memberikan kesimpulan yang kukuh. 
 
Kata kunci: Pengesanan kanser serviks; mRNA HPV; penanda bio  
© 2015 Penerbit UTM Press. All rights reserved 
  
 
 
1.0 INTRODUCTION 
 
According to World Health Organization (WHO) report, 
cervical cancer is the second most diagnosed cancer 
in women and one of the major causes of morbidity 
and mortality worldwide, with approximately 530000 
new cases each year [1]. More than 85% of death 
cases occur in developing countries with lower income 
and poorer hygiene.  Human papillomavirus (HPV) is 
recognized to be leading cause of cervical cancer. It 
belongs to a group of more than 150 non-enveloped 
and double-stranded DNA viruses, with 15 high risk 
(hrHPV) ( Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 68, 73, and 82) and 12 low risk (lrHPV) genotypes. 
Types 16, 18, 31 and 45 are account for majority of 
cervical cancers. Among these, types 16 and 18 are 
collectively associated with majority of cervical 
squamous cell carcinomas and type 18 is mainly 
detected in adenocarcinoma of the cervix [2 -4]. HPV 
infection does not necessarily cause cervical cancer 
as most of the infections are transient with an average 
period of 6–14 months and will be cleared rapidly by 
immune system [4]. Only small number of cases can be 
progressed to cancer due to presence of persistent 
infection which is essential for cervical cancer 
development [5]. Thus, recognition of persistent hrHPV-
caused infections is the key target of HPV DNA testing 
[6]. Cervical cytology techniques including 
Papanicolaou smear and liquid based cytology have 
been used as standard methods of cervical cancer 
screening for around five decades [7]. While Cytology- 
based tests were able to reduce the mortality rate of 
cervical cancer by 80%, other techniques with higher 
sensitivity were still needed since cytological tests were 
limited with low sensitivity and various sampling 
methods. Therefore, alternative techniques such as 
HPV DNA testing have been proposed [8].  hrHPV 
infection is one of the main risk factors of cervical 
cancer progression due to inactivation of tumor 
suppressor genes like RB and p53 genes and allowing 
the tumors to grow unnoticed and blocking the 
spontaneous treatment by immune system [9]. 
  Owing to inability of HPV to grow in culture, 
serological, molecular biology and immunological 
assays should be used to detect these viruses. 
Polymerase chain reaction-based tests are most 
commonly used methods of HPV DNA detection 
followed by Hybrid Capture 2 (HC2) [10]. PCR-based 
assays often based on target amplification with the 
help of multiplex or consensus primers to amplify a 
broad range of HPV types that allows differentiation 
between multiple infections. The Hybrid Capture test is 
a batch test which detects 13 genital high-risk HPV 
types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 
and 68) using a mixture of long synthetic RNA probes. 
HPV DNA tests detect the presence of the viral 
genome in the samples taken from patients while RNA 
tests detect the messenger RNA expression of cancer-
related viral genes. Prediction of the risk of cervical 
cancer would be more accurate by applying HPV 
E6/E7 messenger RNA techniques compare with HPV 
DNA testing as mRNA expression profile shows better 
correlation with the harshness of the lesions. HPV DNA 
detection methods have no ability to distinguish 
between persistent and regressive infections therefore 
these tests are not specific enough for identification of 
the patients at risk of developing cervical cancer [11]. 
Overexpression and deregulation of E6 and E7 viral 
oncogenes is an essential factor for malignant 
transformation of infected cells following HPV 
integration in the host genome [12] [6].  
For our review, PubMed and Medline libraries were 
interrogated with language restricted to English and 
search terms: human papilloma virus, HPV DNA, HPV 
Ribonucleic acid, HPV mRNA, HPV and cervical 
cancer, HPV detection methods, HPV mRNA and CIN, 
sensitivity, specificity and histology. Abstracts and titles 
were independently screened and the studies which 
were completely based on technical features rather 
than sensitivity and specificity were excluded. Final 
inclusions were based on full articles. Our purpose was 
to compare the specificity of HPV mRNA versus DNA 
testing for detecting the risk evaluation of cervical 
cancer progression. We also described the general 
clinical applications of HPV testing to gain better 
insight into the importance of HPV testing in cervical 
cancer care, followed by overview of the studies 
which carried out a comparison of HPV DNA and 
mRNA for their specificity and sensitivity. 
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2.0 POTENTIAL CLINICAL APPLICATIONS OF 
HPV TESTING  
 
Astounding progress has been made towards 
understanding pathology and development of 
cervical cancer in recent years. Several molecular 
viral detection tools have been developed due to 
the important role of HPV as an essential cause of 
cervical carcinogenesis [13-14]. These methods are 
basically relying on detection of viral nucleic acids in 
infected samples taken from patients as HPV cannot 
be cultured (Table1) [14-15]. Potential clinical 
applications of HPV tests classified into four 
categories: primary screening [16-17], triage of cases 
with low grade cervical abnormalities [17-18] follow 
up after treatment of CIN [17] [19] and resolution of 
uncertainty [20] [18]. 
 
 
 
2.1  Primary Screening  
 
The main goal of cervical cancer screening is to 
reduce the morbidity and mortality rate of the 
cancer. Since most cases of the HPV-related benign 
lesions are transient, it is necessary to detect the 
exact lesions that are at the greater risk of 
progressing to invasive cervical cancer and avoid 
unnecessary treatment and pointless discomfort of 
the patients. The newest version of various 
international primary cervical screening cancer 
guidelines were released at year 2012 [21-22]. Based 
on latest recommendations, adding HPV testing 
enhance the sensitivity of screening especially for 
CIN3+ women and may help to increase the length 
of intervals. The guidelines are agreed in the point 
that HPV co-testing is preferred for the women over 
age of 30 with interval of every 5 years. 
 
Table 1 commercial techniques available for Human Papilloma Virus screening 
Techniques 
 
Methodology 
 
Target nucleic 
acid 
 
Manufacturer 
 
PreTect HPV Proofer NASBA amplifications via molecular 
beacons 
mRNA Norchip 
NucliSENS Easy Q NASBA amplifications via molecular 
beacons 
mRNA BioMérieux 
APTIMA HPV Assay Transcription-Mediated Amplification 
(TMA),Dual Kinetic Assay (DKA) 
technology and chemiluminescent 
probe detection 
mRNA Gen-Probe 
 
Hybrid Capture 2 
 
Signal amplification using microplate 
chemiluminescence 
 
DNA 
 
Qiagen 
 
CareHPV 
 
Signal amplification using microplate 
chemiluminescence (spin-off of HC2) 
 
DNA 
 
Qiagen 
 
Roche amplicor HPV 
 
PCR-based test with micro-well plate 
detection 
 
DNA 
 
Roche 
 
Abott real-time HPV 
 
PCR-based with Taqman probe 
detection 
 
DNA 
 
Abbott 
 
Cervista HPV HR 
 
Signal amplification by invader 
chemistry 
 
DNA 
 
Hologic 
 
Cervista HPV 16/18 
 
Signal amplification by invader 
chemistry 
 
DNA 
 
Hologic 
 
MALDI-TOF 
 
Mass spectroscopy with multiplex 
primary PCR 
 
Type specific 
DNA 
 
BioMérieux 
 
Cobas 4800 HPV Test 
 
Nucleic acid amplification based on 
RT-PCR technology 
 
DNA 
 
Roche 
 
HR-HPV 16/18/45 Probe Set 
Test 
 
 
Signal amplification using hybrid 
capture technology 
 
DNA 
 
Qiagen 
 
 
 
2.2 Triage of Cases with Low Grade Cervical 
Abnormalities  
 
Several countries apply HPV testing as one of the 
triage options for low grade cervical lesions. HPV 
triage is suggested to show higher sensitivity than 
repeated cytology and have an approximate same 
sensitivity with immediate colposcopy in case of 
CIN2+ detection. The referral of patients to 
colposcopy will also be reduced by using this test for 
patients with ASCUS. On the other hand, because 
more than 80% of LSIL patients are HPV positive, HPV 
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testing is not able to reduce their referral to 
colposcopy. In a recent meta-analysis paper [23], 
the authors stated that mRNA testing is significantly 
more specific than HC2 testing for detection of CIN2+ 
in women with ASCUS and LSIL while the sensitivity is 
lower and therefore negative mRNA result is not 
reliable enough to prove the absence of CIN2. 
Another investigation [24] was set to study the 
performance of HPV mRNA assay in primary 
screening and triage of women. Endocervical 
samples of subject aged 30 to 50 were tested for 
APTIMA HPV mRNA assay, HC2 and cytology. The 
sensitivity of HC2 and APTIMA assay for detection of 
CIN3+ were higher while in case of specificity 
ThinPrep and APTIMA were significantly better. 
 
2.3 Post Treatment Follow-up of Cervical 
Intraepithelial Neoplasia Cases  
 
Patients who went through local excision or 
conization treatments for their cervical lesions should 
be monitored regularly as these methods do not 
necessarily eradicate HPV and patients remain at risk 
of reappearance of the lesions. In meta-analysis of 11 
studies, Zielinski et al. reported the failure of up to 25% 
of CIN3 treatments [25]. Therefore early detection of 
residual or recurrent CIN after treatment of high 
grade cervical neoplasia is necessary. HPV testing is 
proven to have similar specificity and higher 
sensitivity than other follow-up methods. 520 women 
with negative or low grade biopsies were studied [26] 
to compare the specificity of E6/E7 mRNA test and 
cytology for follow-up application. Results reported 
that mRNA test showed significant higher specificity 
while the sensitivity was quite same. Persson et al. [27] 
designed an experiment for using L1 DNA and high 
risk E6/E7 mRNA as biomarkers for detection of 
residual or recurrent CIN in women treated by 
conization. HPV linear array and APTIMA assays were 
used in this study. HPV DNA assay reported to be 
more sensitive while less specific than APTIMA assay.   
 
2.4  Resolve Uncertainty  
 
Sometimes colposcopy results show patients to be in 
low risk but with some uncertainty. Since HPV testing 
has a high negative predictive value it can be useful 
to resolve the uncertainty of colposcopy results of 
patients entered in colposcopy referral process. 
Bowring et al. [20] studied 755 women over 12 
months, of them two categories showed 90.3% of the 
resolution of uncertainties. HC2 technique was 
applied for HPV testing and their findings proved its 
ability to recognize the patients at higher risks. 
 
 
3.0 HPV E6/E7 mRNA EXPRESSION AND 
PROGRESSION OF CERVICAL CANCER  
 
Cell transforming ability of Human papilloma virus 
relies on over-expression of E6/E7 oncogenes.  HPV E6 
proteins are able to associate with the cellular tumor 
suppressor (p53), resulted in degradation and 
inhibition of its transcriptional regulatory actions. On 
the other hand, E7 proteins possess the ability to 
endorse the degradation of pRb (cellular tumor 
suppressor) through a proteasome-mediated 
pathway and prevent the gene to bind to the 
cellular E2F transcription factors, thus inactivate it. 
Series of immunological responses caused by these 
actions, lead to formation of malignant phenotype 
and destruction of cell cycle regulation. Thus, 
targeting E6/E7 mRNA may result in more trusted 
outcomes than detecting the presence of viral DNA.  
 
 
4.0 OVERVIW OF RECENT CLINICAL TRIALS  
 
4.1  Cross-sectional Studies 
 
Researchers conducted an investigation on 400 
women, previously found to be infected with high risk 
types of HPV, using their cervical specimens for 
detecting HPV DNA along with RNA [28].  hrHPV DNA 
detection was performed by liquid hybridization 
assay. E6 and E7 transcripts of hrHPV RNA were also 
identified using nucleic acid sequence-based 
amplification assay (NASBA) and real-time reverse 
transcription PCR. Findings of this study confirmed 
that monitoring E6 and E7 expression would be a 
better way to identify the risk evaluation of patients 
infected with HPV as the rate of E6 and E7 detection 
were progressively increased by raising the grade of 
patient’s experiential lesions. In another study, 
Rijkaart et al. [29] applied PreTect HPV-proofer for 
detecting E6/E7 HPV mRNA and estimating the risk of 
high grade intraepithelial neoplasia among patients 
infected with hrHPV DNA. hrHPV RNA found to be  
higher in cases with more sever cytological 
abnormalities, as around 63% of women with CIN2 
and above have been diagnosed with positive 
results in compare with 32% in other patients.  
In recent years, biomarkers that highlight the 
occurrence of transformation of HPV infected cells 
attracted the interest of many scientists around the 
world. In one experiment, researchers studied the 
performance of HPV mRNA, HPV DNA and p16INK4a-
cytology to detect high grades of cervical dysplasia 
in patients diagnosed with abnormal cytology [30].  
Liquid based cytology specimens of totally 275 
women with median age of 36 years were taken. 
CINtec p16INK4a-cytology assay has been applied 
for p16INK4a-cytology followed by APTIMA HPV 
mRNA assay and Hybrid Capture 2 (HC2). Results of 
the study revealed that there were no great 
differences in sensitivity of the tests for identification 
of CIN3+ and CIN2+ patients as all of the tests 
showed high sensitivity, however specificity were 
higher in case of APTIMA and CINtec assays. 
Therefore HPV mRNA and p16INK4a-cytology tests 
would give more accurate results in compare with 
HPV DNA detection.  
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A total of 105 HPV DNA-infected women with 
abnormal Pap smear test were undergone a study by 
Salimovi´c-Beˇsi´ et al. [31] This research aimed to 
compare type specific DNA and E6/E7 mRNA based 
assays for detection of HPV-16, 18, 31, 33, and 45. 
Human papilloma virus typing was carried out using 
multiplex real-time PCR. Type-specific real-time 
NASBA assay was also performed for determination 
of HPV messenger RNA. Severity of cervical cytology 
has been found to be in direct relation with 
increasing hrHPV-caused infections. Lower 
identification rate of mRNA assay were lower in 
patients with atypical squamous cells, however the 
authors recommended to study the role of hrHPV 
E6/E7 mRNAs in future studies. In another study, 
Cattani et al. [32] tried the possibility of using E6 and 
E7 transcripts of HPV genome as reliable markers for 
detection of cervical cancer progression. Total of 180 
patients with median age of 35 years underwent 
cytology and colposcopy tests. Patients diagnosed 
with suspicious lesions were also subjected to biopsy 
test. Hybrid Capture 2 system was executed to 
detect HPV DNA followed by real-time multiplex 
nucleic acid sequence-based amplification to 
detect HPV E6 and E7 mRNA. Transcripts of HR HPV 
types were also detected by NucliSens EasyQ HPV 
assay. Results of this study indicated the strong 
association between the level of HPV DNA and RNA 
detection and grade of the lesion. The sensitivity of 
HPV RNA and DNA tests were approximately same 
while RNA test presented higher specificity and 
positive predictive value which makes it stronger 
marker for prediction of cervical cancer 
development than HPV DNA test.  
The most important key factor in screening the risk 
of cervical cancer is to identify the hrHPV positive 
patients who are at the higher risk of high grade 
intraepithelial neoplasia (CIN 3) and invasive cervical 
cancer development. Molecular biomarkers related 
to HPV can be served as effective tools to improve 
the success of screening and prediction of 
predominant cervical lesions. Varnai et al. [33] 
performed a diagnostic and prognostic study on a 
total of 66 women infected with at least one of HPV 
16, 18, 31, 33 and 45 types and cytology results from 
normal to high-grade squamous intraepithelial 
lesions. PreTect HPV-proofer used to detect the 
expression of E6/E7 transcripts from the same HPV 
types. Cervical situation was also monitored 18 
months after the messenger RNA test. The sensitivity 
of E6/E7 mRNA detection was approximately 100% 
for prevalent CIN3 lesions screening. Very high 
negative predictive value was gained for disease 
development throughout the normal course of HPV 
infection. Outcomes of this research were indicative 
of the fact that E6/E7 messenger RNA can be count 
as a strong predictive marker to increase the 
efficiency of screening methods.  
HPV mRNA and DNA based methods were 
compared by Lie et al. [34], recruiting 383 patients 
with median age of 35 years and positive cytology 
for either squamous or glandular lesions. All patients 
went through specimen collection with Cervex-Brush. 
Samples were analyzed by Pap smear and histology 
tests along with Hybrid Capture II and PreTect HPV-
proofer for detection of HPV. Some of the samples 
were also used for PCR and sequencing techniques. 
HPV mRNA was detected in all the cases with 
invasive carcinoma and DNA or mRNA of high-risk 
Human papilloma virus types were present in 90% of 
samples. Histologically confirmed high grade lesions 
(CIN2+) were found to be positive for HPV DNA in 275 
and HPV mRNA in 225 out 291 patients. Results of this 
study suggested that these HPV tests are able to 
improve the detection rate of high-grade cervical 
neoplasia while mRNA test is more suitable for 
cervical cancer risk assessment.  
Human papilloma virus DNA and messenger RNA 
detection were compared by Moldet et al. [35] in a 
cross sectional study of 4136 women. Women were 
subjected to 2 years follow up for high-grade 
squamous intraepithelial lesions histologic 
confirmation during the research and results were 
compared to results of the study. Samples were 
collected using Cervex Brush and HPV DNA 
detection was performed by consensus Gp5+/6+ 
PCR and HPV type specific PCR for HPV types 16, 18, 
31, 33 and 45. Besides, PreTect HPV-proofer test was 
used for HPV mRNA detection. A total of 166 women 
were diagnosed with cytological abnormality by Pap 
smear test. The specificity and positive predictive 
value of Gp5+/6+ consensus PCR for detection of 
cytological HSIL was found to be 90% and 3.7%  
respectively in compare with 97.3% and 10.3% for 
HPV mRNA detection using PreTect HPV-Proofer. In 
case of histologic CIN2+ detection sensitivity and 
positive predictive value of Gp5+/6+ consensus PCR 
were also found to be 66.7 and 81.3 respectively 
compared with 88.9% and 92.3% for PreTect HPV-
Proofer. The study results concluded that HPV mRNA 
detection would be a promising method. In a recent 
study by Liverani et al. [36] the authors assessed 
detection of HPV mRNA transcripts of HPV types 
16,18,31,33 and 45 along with frequency of HPV DNA 
genotypes in 134 patients diagnosed with cervical 
intraepithelial neoplasia CIN 2+. 85.8% (n=115) of 
cases were found to be infected with hrHPV types, of 
which 68 were positive for HPN DNA and 50 were 
positive for HPV mRNA of five most common 
carcinogenetic HPV types. Based on their study 
results, the authors theorized that the replication 
stage of hrHPV may be revealed by mRNA testing 
other than its physical rate. 
In a paper by Sotlar et al. [37] cervical scrapes 
sample of patients were examined for detecting 
oncogene spliced/unsplicedE6/E7 transcripts of 14 
high risk HPV types by nested RT-polymerase chain 
reaction. HPV DNA detection was carried out on 
1699 samples by nested multiplex PCR and out of 
these 799 high-risk HPV DNA positive samples used for 
mRNA detection. E6/E7 detection was visibly 
increased with severity of lesions, with 18%, 58%, 77% 
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and 84% from no CIN to CIN3.  The sensitivity of using 
hrHPV E6/E7 mRNA as biomarker for detection of CIN 
lesions was lower than HPV DNA. In contrast HPV 
mRNA showed higher specificity rate. The results of 
previous study was supported by the work of same 
researcher [38] who stated that, detection of hrHPV 
E6 and E7 mRNA transcripts, improves the specificity 
of cervical intraepithelial neoplasia screening. 
Nested RT-PCR was again used as a tool to detect E6 
and E7 oncogenes in cervical samples of 779 hrHPV-
DNA-positive patients, diagnosed with all grades of 
CIN. The results were same to previous study, as HPV 
E6 and E7 mRNA prevalence were increased by 
increasing the level of CIN. Specificity and positive 
predictive values were also higher in case of HPV 
mRNA than HPV DNA detection.  
CIN 2+ detection in women younger than 30 years 
old mainly depends on cytology due to the fact that 
transient HPV infections were shown to be higher in 
this group [39-40]. In order to overcome this issue, 
Pierry et al. [40] tested intracellular HPV E6, E7 mRNA 
quantification for prediction of high-grade cervical 
intraepithelial using cytology specimens of 3133 
women aged 19–75 years. Their findings 
demonstrated no huge difference between the 
sensitivity of E6/E7 mRNA quantification and 
abnormal cytology for CIN2+ and CIN3+ detection 
while the specificity was significantly higher by E6/E7 
mRNA detection. In a study which set out to use 
Increased levels of HPV16 E6*I  mRNA as a diagnostic 
biomarker to detect CIN2+, Kosel, et al. [41] analyzed 
cervical samples of 301 HPV16 positive women with 
normal cytology, ASCUS, mild-to-moderate or severe 
dysplasia to quantify the levels of HPV16 DNA and 
HPV16 E6*I mRNA using real time PCR. Levels of 
HPV16 E6*I mRNA transcripts were significantly 
correlated with severity of the abnormality. Positive 
predictive value of detecting CIN2+ was also 
considerably higher with increasing the level of 
detected transcripts.  
A recent study by Liu et al. [42] involved applying 
QuantiVirus®HPVE6/E7 mRNA test on cervical 
cytological samples of 335 patients to identify CIN2+. 
Severity of the cytological and histological diagnosis 
was shown to be positively correlated with 
prevalence of HPV E6/E7 mRNA. Castle et al. [43] 
reaches same conclusions, finding carcinogenic 
HPVE6/E7 mRNA as a potential biomarker to detect 
cervical pre-cancer and cancer as they found an 
enhancing probability of testing positive for 
HPVE6/E7mRNA with increasing intensity of cytology 
and histology. Waldstrom and Ornskov [44] discussed 
about the clinical performance of linear array HPV 
genotyping (LA) (HPV DNA detection) and APTIMA 
HPV assay (HPV mRNA detection) on consecutive 
PreservCyt samples of women with atypical 
squamous cells of undetermined significance (ASC-
US). The specificity and positive predictive value of 
mRNA detection was shown to be significantly higher 
in CIN2+ and CIN3+ whereas DNA detection 
exhibited higher sensitivity in case of CIN2+. Data 
from Kottaridi et al. [45] study have identified the 
clinical performance of flow cytometric detection of 
HPV mRNA versus HPV DNA array technology for 
detection of high grade cervical lesions. Liquid based 
cytology samples of totally 189 women with 
confirmed histology were screened for presence of 
HPV mRNA and DNA. The specificity of HPV mRNA 
detection by OncoTect assay was shown to be 
significantly higher than HPV DNA detection, thus the 
authors stated that mRNA detection with flow 
cytometry can be a powerful tool for detection of 
high grade lesions which is able to reduce the 
unnecessary referral of the patients for colposcopy. 
 
4.2  Prospective Cohort Studies  
 
77 women diagnosed with atypical cells of 
undetermined significance (ASCUS) and low-grade 
squamous intraepithelial lesion (LSIL), joined to 
Norwegian cervical cancer screening program 
(NCCSP) for 2-year follow-up study performed by 
Molden et al. [46].  The aim of this research was to 
predict cervical intraepithelial neoplasia (CIN) 2+ by 
detection of HPV mRNA and DNA with Gp5+/6+ 
consensus PCR and PreTect HPV-Proofer. The 
sensitivity of both tests for diagnosing CIN2+  were 
around 85.7% during 2 years of follow up. However 
PreTect HPV-proofer presented higher specificity.  The 
overall outbreak of HR-HPV (types 16, 18, 31, 33 and 
45) mRNA was shown to be 23.4% which was nearly 
half of HPV DNA (54.6%). Although the overall 
detection rate of HPV mRNA was lesser, most of the 
histological CIN2+ cases were detected during the 
follow-up. The consequences of this research 
recommend that, women with positive ASCUS/LSIL 
Pap smear and positive mRNA should go through 
more follow ups than women with negative mRNA 
tests. In another investigation [47], mRNA detection 
was performed on 53 women with normal cytology 
and positive HPV DNA results. Cytology assessment 
and HPV genotyping were repeated after 2 or 3 
years. The results of study indicate higher possibility of 
persistent infection for women who were mRNA 
positive at the baseline. 
 
 
5.0  IS RNA A SUITABLE BIOMARKER 
 
One of the limitations of working with mRNA is the 
instability of RNA as a single stranded moiety in 
compare with DNA, as results of Castle et al. [48] 
study on archived liquid-based cervical specimens of 
9205 sexually active women suggested that, HPV 
DNA in exfoliated cervical cells can be well 
preserved in particular types of liquid based cytology 
medium.  
Waldstrøm and Ørnskov [49] tested the sensitivity 
and specificity of HPV mRNA test (APTIMA HPV mRNA 
assay) on remaining supplies of 3 year old preservCyt 
low grade squamous intraepithelial lesion samples of 
405 women. They achieved 92.5% and 38.2% of 
221                                             Eko Supriyanto et al. / Jurnal Teknologi (Sciences & Engineering) 75:1 (2015) 215–224 
 
 
75:1 (2015) 215–224 | www.jurnalteknologi.utm.my | eISSN 2180–3722 | 
sensitivity and specificity of messenger RNA assay 
respectively for identifying CIN2+ followed by 93.9% 
and 35.5% for CIN3+. Their findings suggested that 
using mRNA would be an effective method for 
identifying patients with low grade squamous 
intraepithelial lesions. Cuschieri et al. [50] were also 
performed an investigation on evaluation of HPV 
mRNA detection in liquid based cytology cervical 
specimens and checked the stability of RNA over 14 
days of sample collection.  
 
Table 2 Summaries of published clinical tria 
 
Authors Year Country 
Total 
sample 
size 
Age 
range 
(mean) 
Recruitment setting HPV DNA test 
HPV mRNA 
test 
Cattani et 
al. 
2009 Italy 400 21-59 hrHPV DNA infection 
Liquid 
hybridization  
NASBA and 
real-time RT-
PCR 
Rijkaart et 
al. 
2012 
Netherland
s 
375 30-60 
Normal cytology, 
borderline ,mild, 
moderate or worse 
dyskaryosis   
GP5+/6+ PCR 
PreTect HPV-
Proofer 
Reuschenb
ach et al. 
2010 Germany 275 
28-44 
(36) 
Abnormal cytology or 
follow-up after previous 
treatment for cervical 
dysplasia 
HC2 
APTIMA HPV 
assay 
Salimovi´c-
Beˇsi´  et 
al.l 
2013 
Bosnia and 
Herzegovin
a 
105 19-62 
 Positive hr HC2 or 
Abbott Real-Time hrHPV 
screening , abnormal  
Pap smear 
Multiplex real-
time PCR 
Type-specific 
real-time 
NASBA 
Cattani et 
al. 
2009 Italy 180 
20-77 
(35) 
secondary screening 
 
HC2 
NucliSens 
EasyQ HPV 
assay 
Varnai et 
al. 
2008 
Hungary- 
Germany 
66 ___ 
Normal to high-grade SIL 
at baseline, hrHPV DNA 
positive 
MY09/MY11 and 
GP5+/6+ PCR 
PreTect HPV-
Proofer 
Lie et al. 2005 Norway 83 
19-85 
(35) 
Squamous or glandular 
lesions 
HC2 
PreTect HPV-
Proofer 
Molden et 
al. 
2005 Norway 77 >30 
ASCUS and LSIL Pap 
smear 
Gp5+/6+ 
consensus PCR 
PreTect HPV-
Proofer 
Molden et 
al. 
2005 Norway 4136 30-69 LSIL and  HSIL 
Gp5+/6+ PCR 
and HPV type 
specific PCR 
PreTect HPV-
Proofer 
Liverani et 
al. 
2012 Italy 1113 (36.7) CIN2 and above PCR 
PreTect HPV-
Proofer 
Sotlar et al. 2004 Germany 
1699 
 
___ 
All grades of 
CIN  
Nested 
multiplex PCR 
Nested RT-
PCR 
Sotlar et al. 2005 Germany 779 ___ 
hr-HPV positive exhibiting 
all grades of CIN 
Nested 
multiplex PCR 
Nested RT-
PCR 
Pierry et al.l 2012 USA 3133 19-75 
LSIL, HSIL , ASCUS and 
positive for HPV DNA  
___________ 
HPV 
OncoTect 
Kosel et al. 2007 Germany 301 
17-57 
( 31 ± 
7.7) 
HPV 16 positive  RT-PCR RT-PCR 
Liu et al. 2014 China 335 ___ 
Abnormal cytology, 
atypical squamous cells 
of unknown significance 
or higher, or a positive 
HPV DNA test 
QuantiVirus®HPV 
DNA diagnostic 
kit 
QuantiVirus®
HPV E6/E7 
mRNA test 
Castle et 
al. 
2007 USA 540 ___ 
Normal, ASC, LSIL and 
HSIL cytology or worse. 
LA, HC2 
APTIMA HPV 
assay 
Waldstrom 
and  
Ornskov 
2011 Denmark 369 >30 
Women with cytological 
diagnosis of ASCUS 
LA 
APTIMA HPV 
assay 
Kottaridi et 
al. 
2011 Greece 189 21-65 
Women with 
histologically confirmed 
lesions 
 
HPV DNA array 
OncoTect 
assay 
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LBC samples were taken in PreservCyt®   from 7 
women with cytological report of moderate or 
severe dyskaryosis RNA extraction has been done at 
6 hours (baseline) and 4, 7 and 14 days after 
collection of samples. PreTect HPV Proofer used for 
detection of HPV mRNA with human U1 small 
ribonucleoprotein (U1A mRNA) as a control. Linear 
array HPV DNA genotyping were also performed with 
the aim of detecting HPV types other than 16, 18, 31, 
33 and 45 that women may have been infected with. 
5 out of 7 samples were mRNA positive from the base 
line (four samples with HPV type 16 and one sample 
with HPV type 45) up to 14 days. 2 remaining samples 
were found to be HPV mRNA negative. Study 
conclusions stated that RNA can be detected in 
normally collected LBC specimens for at least 14 
days. 
In another experiment performed on liquid based 
cytology specimens, Tarkowski et al. [51] tried to 
improve detection of isolated viral RNA by seeding 
serial dilutions of a human papillomavirus 16 positive 
cell lines on PreservCyt medium. Their findings 
showed that this method is suitable to produce 
appropriate HPVE6/E7 transcripts after 1 year of 
storage. Molecular quality of routine exfoliated 
cervical cytology has been checked for the effect of 
different sample collection methods and mediums 
on the yield of RNA in the study by Habis et al [52].  
Various collection mediums included different tissue 
culture medium, high salt solutions, cationic 
detergent-based surfactant, alcohol-based 
collection fluids and MTM along with 2 different 
commercial extraction kits (Master Pure Complete 
DNA and RNA Purification and RNAwiz) have been 
used. The outcome of this examination revealed that 
collection medium had the highest effect on the 
quantity and quality of RNA as PAXgene and 
methanol-based PreservCyt which are widely used in 
clinical settings showed higher yield of RNA 
compared with other mediums.  
One of the most critical points in detecting the risk 
evaluation of cervical cancer progression is to grade 
cervical lesions. Misdiagnosis of the lesions may results 
in over or under-treatment of the patients which can 
be life threatening. Evans et al. [53], applied CIN/SIL 
grading by using hrHPV E6/E7mRNA chromogenic in  
situ hybridization (CISH) signal patterns as biomarkers 
and RNAscope assay as a new method of detection. 
Their findings support the ability of the hrHPV 
E6/E7mRNA CISH as a biomarker for CIN histological 
grading. 
 
 
6.0 CONCLUSION 
 
Over the years scientists intend to use their best 
efforts to find novel relevant biomarkers and improve 
the efficacy of cervical cancer screening. There are 
number of recent overviews available [54-58]. The 
current review tried to describe E6/E7 mRNA 
expression as a biomarker of transforming viral 
infection. It does not required highly specialized 
stages and can be easily adapted to future 
operations. There are studies and evidences 
suggested that HPV mRNA might be a relevant 
diagnostic biomarker but if the debate is to be 
moved forward, additional studies and more clinical 
data needs to be developed in order to make strong 
conclusion.    
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